WORCESTER, Mass., June 18, 2008 (PRIME NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (http://www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that it will hold a conference call on Tuesday, June 24, 2008 at 11 a.m. Eastern Time to update the investment community on its Phase III clinical trial of the Company's flagship product, Generex Oral-lyn(tm), an oral insulin spray, activity in the regions where the Company's products have been approved for sale, and progress at its Antigen Express wholly-owned subsidiary.
